Results 101 to 110 of about 42,801 (258)

Cross‐sectional and longitudinal associations of cannabis use with cognitive functioning in individuals with a cannabis use disorder: The moderating role of nicotine

Addiction, EarlyView.
Abstract Background and Aims Cannabis is among the most widely used psychoactive substances globally and is often consumed alongside tobacco. Cannabis use has been associated with impairments in attention, learning, and memory, whereas nicotine can acutely enhance, but chronically impair, certain cognitive functions.
Emese Kroon, Nora de Bode, Karis Colyer‐Patel, Jia Hua Hsieh, Francesca Filbey, Janna Cousijn   +5 more
wiley   +1 more source

Brain reward function in young people with cannabis use disorder: A functional magnetic resonance imaging study

Addiction, EarlyView.
Abstract Background and Aims Cannabis use disorder (CUD) affects ~50 million people globally. Neuroscientific theories suggest that a blunted neural response to non‐drug rewards is a hallmark of substance use disorders; however, this remains untested in CUD. The current study tested whether brain reward system responses to the anticipation and feedback
Martine Skumlien, Lisa‐Marie Greenwood, Arush Honnedevasthana Arun, Isabella Goodwin, Anastasia Paloubis, Tribikram Thapa Rana, Marianna Quinones Valera, Eugene McTavish, Gabrielle Abbott, Suraya Dunsford, Antonio Verdejo‐Garcia, Jessica Ramamurthy, Mark M. Schira, Nadia Solowij, Chao Suo, Valentina Lorenzetti   +15 more
wiley   +1 more source

Beyond abstinence: Redefining success in cannabis use disorder treatment

Addiction, EarlyView.
Abstract Background Over two decades of pharmacotherapy research has yet to yield a consistently effective medication for cannabis use disorder (CUD), in part because clinical trials have frequently prioritized abstinence as a primary or key endpoint.
Tobias B. Atkin, Frances R. Levin, John Mariani, Christina A. Brezing   +3 more
wiley   +1 more source

Psychological change processes in alcohol use disorder: A qualitative study of 5‐methoxy‐N,N‐dimethyltryptamine (5‐MeO‐DMT) with cognitive behavioural therapy

Addiction, EarlyView.
Abstract Background and aims This study qualitatively explored psychological change processes as described by participants and therapists within a phase 2a clinical trial evaluating the safety, tolerability, and preliminary efficacy of a single dose of intranasal 5‐methoxy‐N,N‐dimethyltryptamine (5‐MeO‐DMT; BPL‐003) administered alongside psychological
Mathieu Seynaeve, Fiona Dunbar, Anna O. Ermakova, Luke Mitcheson, James J. Rucker, Anthony Cleare, John Marsden   +6 more
wiley   +1 more source

Cannabis use disorder in patients prescribed medical cannabis—Should we consider prescription cannabis use disorder as a new diagnostic condition?

Addiction, EarlyView.
Abstract Background and Aims The introduction of prescribed medical cannabis in many parts of the world raises issues regarding how we conceptualise Cannabis Use Disorders (CUD). The Diagnostic Statistical Manual Version 5 (DSM5) provides a framework for ‘Prescription Cannabis Use Disorder’ (Pr‐CUD) when a person is using medical cannabis only‐as ...
Nicholas Lintzeris, Llewellyn Mills
wiley   +1 more source

From allostasis to addiction: Cortisol dysregulation, daily stress and relations with 9‐year alcohol and substance use disorder severity in community adults

Addiction, EarlyView.
Abstract Background and aims Diurnal cortisol dysregulation and daily stressor severity may jointly forecast long‐term alcohol use disorder (AUD) and substance use disorder (SUD) severity, yet most evidence is cross‐sectional and relies on single cortisol indices.
Nur Hani Zainal, Natalia Van Doren
wiley   +1 more source

Prescribed alternative stimulants among people who use unregulated stimulants: Examining the association between maximum dose reached and medication discontinuation in the first 3 years of implementation in British Columbia, Canada

Addiction, EarlyView.
Abstract Background and aims In 2020, British Columbia (BC), Canada, introduced ‘Prescribed Alternatives’ (PA) as an approach to offering regulated substances to people accessing the unregulated supply. This study aimed to estimate and compare prescribing characteristics of dextroamphetamine and methylphenidate stimulant PAs in BC, to estimate ...
Bin Zhao, Kevin Hu, Roshni Desai, Shania Au, Kali‐olt Sedgemore, Vitor Tardelli, Addie Carter, Paxton Bach, Christian Schutz, Amanda Slaunwhite, Alexis Crabtree, Heather Palis   +11 more
wiley   +1 more source

Towards the implementation of cannabis‐focused apps in early intervention services for psychosis: A qualitative investigation of patient and clinician perspectives

Addiction, EarlyView.
Abstract Background and aims Cannabis use is highly prevalent among young adults with first‐episode psychosis (FEP) and is associated with poorer clinical and functional outcomes. Mobile health interventions may help address structural barriers to delivering cannabis‐focused psychosocial interventions within early intervention services (EIS), yet ...
Selim Abou‐Rahal, Alexis Doucet, Pamela Lachance‐Touchette, Amal Abdel‐Baki, Stephanie Coronado‐Montoya, José Côté, Ovidiu Tatar, Philip G. Tibbo, Didier Jutras‐Aswad   +8 more
wiley   +1 more source

Daily affect profiles during addiction recovery: Transition dynamics and links to acute recovery outcomes. [PDF]

Addict Behav
Lancaster JH, Brick TR, Apsley HB, Cleveland HH.   +3 more
europepmc   +1 more source

Cannabis use and cannabis use disorder among older adults in the USA

Addiction, EarlyView.
Abstract Background and aims Cannabis use is increasing among older adults in the United States (US); however, little is known regarding details of use or cannabis use disorder (CUD) in this population. This study aimed to describe cannabis use and CUD among older adults in the US.
Benjamin H. Han, Evan L. Eschliman, Joseph J. Palamar, Mireia Triguero Roura, Pia M. Mauro   +4 more
wiley   +1 more source